Vivus is a biopharmaceutical company focused on obesity and erectile dysfunction. At the time of our financing in 2008, Vivus wanted to fund its phase 3 ED program, but investors were focused on the obesity program. Deerfield financed this program with $30 million by purchasing $10 million worth of stock and by funding a new corporation to hold the IP with $20 million over a period of 15 months.